Download English

Press release |
IBA PARTNER PET NET EXPANDS ITS RADIOPHARMACEUTICALS NETWORK IN GERMANY THROUGH
COLLABORATION WITH UNIVERSITY HOSPITAL OF MUNICH
New radiopharmaceutical development center highlights IBA’s partnerships with industry leaders in
local markets
Louvain-la-Neuve, August 02, 2011 – Ion Beam Applications (IBA) S.A., global developer of next generation
radiopharmaceuticals used in molecular imaging, announced today that its German partner, PET Net GmbH,
has reached an agreement with the University Hospital of Munich to enter a Public-Private Partnership which
aims at installing a new center for radiopharmaceutical development and production in Germany. This
agreement highlights IBA’s commitment to expanding in nuclear medicine markets through key partnerships in
parallel to its organic growth.
The project will provide 15 million euros in financing to build a 1050 m² state-of-the-art center for
radiopharmaceutical development and production that will focus on Positron Emission Tomography (PET), a
non-invasive method used in molecular imaging to visualize biological processes for the early detection and
real-time monitoring of cancer and other diseases. The partnership will focus on the development of new PET
radiopharmaceuticals and the production of existing diagnostic tracers. The facility will be built near the
existing nuclear medicine clinical center at the Grosshardern University Hospital, currently one of the leading
PET examination clinics in Europe.
“Through this collaboration, PET Net has achieved a major step forward in expanding its radiopharmaceuticals
network in Germany, and we are delighted to have them as our German partner,” said François Labarre,
president, IBA Molecular Europe. “Not only are plans for this new center testimony to PET Net’s strength in
the German market and its potential for growth, they also confirm that IBA is committed to partnering with
companies that we have identified as industry leaders.”
In April 2011, IBA announced that it had made a 25.2% minority stake investment in PET Net, a provider of PET
radiopharmaceuticals to nuclear medicine facilities in Germany, in order to strengthen its PET infrastructure in
Germany with a local partner. PET Net is experienced in the management of centers for the production of
radiopharmaceuticals, regulatory affairs and manufacturing licensees and currently manages two production
sites in Erlangen and Regensburg, Germany.
###
Press release | August 02, 2011
1|2
IBA | Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | Tel.: + 32 10 47 58 11 | Fax: + 32 10 47 58 10 | E-mail: [email protected]
| www.iba-worldwide.com | RPM Nivelles | VAT: BE 0428.750.985
Press release |
About PET Net
PET Net GmbH was founded in 1998 by Prof. Dr. med. h.c. Willi Kalender, Ph.D. The production sites in Erlangen and
Regensburg work closely with the University of Erlangen and the University hospital of Regensburg. PET Net’s main
interest is to develop and supply positron-emitting radiopharmaceuticals in Germany and its European neighbors. For
more information, visit www.petnet-gmbh.de
About IBA
IBA group develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare
with a focus on cancer diagnosis and therapy. Its molecular imaging business unit develops, manufactures and distributes
radiopharmaceutical products and supporting services on a global scale. With radiopharmaceutical development-todelivery capabilities that address indications in neurology and Alzheimer’s Disease detection, oncology and cellular death
imaging and cardiology, in PET, SPECT and therapy, IBA has engineered a strong and unique product portfolio and pipeline
of diagnostic tracers aimed at contributing to the development of the global trend towards personalized medicine and
making molecular imaging a major discipline in healthcare. The company also provides educational, technical and
marketing support to medical specialists worldwide to help better respond to patient needs. IBA was awarded Frost &
Sullivan’s European Radiopharmaceuticals Technology Leadership of the Year prize in 2010.
Listed on the pan-European stock exchange EURONEXT, IBA group is included in the BelMid Index. (IBA: Reuters IBAB.BR
and Bloomberg IBAB.BB). Please visit www.iba-worldwide.com for more information.
Contacts
PET Net
Erika Haschke
PET Net, Wetterkreuz 21, 91058 Erlangen
Tel: +49 9131 90867919
[email protected]
IBA
Antoine Jacques
Marketing Europe
Tel: +33 1 69 85 76 65
[email protected]
Media Inquiries :
Christina Aplington
Tel: +33 1 42 22 24 10
[email protected]
Sandrine Leriche
Corporate Communication
Tel: +32 10 47 58 90
[email protected]
Press release | August 02, 2011
2|2
IBA | Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | Tel.: + 32 10 47 58 11 | Fax: + 32 10 47 58 10 | E-mail: [email protected]
| www.iba-worldwide.com | RPM Nivelles | VAT: BE 0428.750.985